Drug addiction remains one of the most significant preventable public health crises in the United States. Researchers at Stanford have designed a combination therapeutic intended to address this critical unmet healthcare need.
Stanford researchers have developed a genome engineering platform for generating genetically precise human cellular models of Lowe syndrome, a rare inherited disorder frequently associated with severe ocular complications, including early-onset glaucoma.
Stanford researchers have developed antisense oligonucleotides (ASOs) that selectively block pathological cryptic exon inclusions in key neuronal genes to treat TDP-43-related neurodegenerative diseases.
KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Researchers from Stanford University and the Technical University of Munich (TUM) propose a new approach for treating Type 2 Diabetes (T2D) by targeting the cathelicidin gene expression pathway.
Huntington's Disease and other ataxias are devastating diseases without any cure or treatment. They are caused by the formation of toxic oligomeric and the aggregation of the Huntintin (HTT) protein.
Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Stanford scientists have discovered novel high molecular weight isoforms of thymic stromal lymphopoietin (TSLP), measured using nanoimmunoassay (NIA), that can serve as a blood-based biomarker for the diagnosis and prognostication of acute graft versus host disease (aGVHD).
Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.
Researchers from Stanford have developed a novel topical pharmaceutical composition comprising of a chemical inhibitor encapsulated in nanomicelles for the treatment of vision loss associated with acute optic neuropathies.